REFERENCES
1. Gatto L, Prati F. Subclinical atherosclerosis: how and when to treat it? Eur Hear J Suppl 2020;22:E87-90.
2. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016;27:473-83.
3. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551.
4. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 2009;50:S376-81.
5. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-19.
6. Gimbrone MA, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016;118:620-36.
7. Orekhov AN, Myasoedova VA. Low density lipoprotein-induced lipid accumulation is a key phenomenon of atherogenesis at the arterial cell level. Vessel Plus 2019;3:3.
8. Mezentsev A, Bezsonov E, Kashirskikh D, et al. Proatherogenic sialidases and desialylated lipoproteins: 35 years of research and current state from bench to bedside. Biomedicines 2021;9:600.
9. Orekhov AN, Tertov VV, Mukhin DN, et al. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem Biophys Res Commun 1989;162:206-11.
10. Orsó E, Grandl M, Schmitz G. Oxidized LDL-induced endolysosomal phospholipidosis and enzymatically modified LDL-induced foam cell formation determine specific lipid species modulation in human macrophages. Chem Phys Lipids 2011;164:479-87.
11. Zhang CP, Ding XX, Tian T, et al. Impaired lipophagy in endothelial cells with prolonged exposure to oxidized low-density lipoprotein. Mol Med Rep 2020;22:2665.
12. Jauhiainen M, Ehnholm C, Gabbasov ZA, et al. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation in human aortic intimal cells - the role of lipoprotein aggregation. Clin Chem Lab Med 1992;30:171-8.
13. Zakiev ER, Sobenin IA, Sukhorukov VN, et al. Carbohydrate composition of circulating multiple-modified low-density lipoprotein. Vasc Health Risk Manag 2016;12:379.
14. Malle E, Waeg G, Schreiber R, et al. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 2000;267:4495-503.
15. Delporte C, Van Antwerpen P, Vanhamme L, et al. Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflamm 2013;2013:971579.
16. Chellan B, Rojas E, Zhang C, et al. Enzyme-modified non-oxidized LDL (ELDL) induces human coronary artery smooth muscle cell transformation to a migratory and osteoblast-like phenotype. Sci Rep 2018;8:1-14.
18. Apostolov EO, Ok E, Burns S, et al. Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophages. J Atheroscler Thromb 2013;20:878.
19. Ravandi A, Kuksis A, Shaikh NA. Glucosylated glycerophosphoethanolamines are the major LDL glycation products and increase LDL susceptibility to oxidation: evidence of their presence in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20:467-77.
20. Alipov VI, Sukhorukov VN, Karagodin VP, et al. Chemical composition of circulating native and desialylated low density lipoprotein: what is the difference? Vessel Plus 2017;1:107-15.
21. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-61.
22. Rudenko G, Henry L, Henderson K, et al. Structure of the LDL receptor extracellular domain at endosomal pH. Science 2002;298:2353-8.
23. Goldstein JL, Ho YK, Basu SK, et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333.
24. Kodama T, Reddy P, Kishimoto C, et al. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci USA 1988;85:9238.
25. Steinbrecher UP, Parthasarathy S, Leake DS, et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;81:3883-7.
26. Morel DW, Hessler JR, Chisolm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983;24:1070-6.
27. Friedman P, Hörkkö S, Steinberg D, et al. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem 2002;277:7010-20.
28. Yia-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Investig 1989;84:1086.
29. Burtenshaw D, Kitching M, Redmond EM, et al. Reactive oxygen species (ROS), intimal thickening, and subclinical atherosclerotic disease. Front Cardiovasc Med 2019;6:89.
30. Gao S, Zhao D, Qi Y, et al. Circulating oxidized low-density lipoprotein levels independently predict 10-year progression of subclinical carotid atherosclerosis: a community-based cohort study. J Atheroscler Thromb 2018;25:1032.
31. Anggraeni VY, Emoto N, Yagi K, et al. Correlation of C4ST-1 and ChGn-2 expression with chondroitin sulfate chain elongation in atherosclerosis. Biochem Biophys Res Commun 2011;406:36-41.
32. Williams KJ. Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Curr Opin Lipidol 2001;12:477-87.
33. Kaplan M, Aviram M. Macrophage plasma membrane chondroitin sulfate proteoglycan binds oxidized low-density lipoprotein. Atherosclerosis 2000;149:5-17.
34. Adhikara IM, Yagi K, Mayasari DS, et al. Chondroitin sulfate N-acetylgalactosaminyltransferase-2 impacts foam cell formation and atherosclerosis by altering macrophage glycosaminoglycan chain. Arterioscler Thromb Vasc Biol 2021;41:1076-91.
35. Steinberg D, Witztum JL. History of discovery: oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30:2311-6.
36. Tertov VV, Sobenin IA, Kaplun VV, et al. Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro. Free Radic Res 1998;29:165-73.
37. Rhoads JP, Major AS. How oxidized low-density lipoprotein activates inflammatory responses. Crit Rev Immunol 2018;38:333-42.
38. Maiolino G, Rossitto G, Caielli P, et al. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm 2013;2013:714653.
39. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002;8:1211-7.
40. Wen Y, Leake DS. Low density lipoprotein undergoes oxidation within lysosomes in cells. Circ Res 2007;100:1337-43.
41. Ahmad F, Leake DS. Antioxidants inhibit low density lipoprotein oxidation less at lysosomal pH: a possible explanation as to why the clinical trials of antioxidants might have failed. Chem Phys Lipids 2018;213:13.
42. Ahmad F, Leake DS. Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages. J Lipid Res 2019;60:98.
43. Kattoor AJ, Pothineni NVK, Palagiri D, et al. Oxidative stress in atherosclerosis. Curr Atheroscler Rep 2017;19:42.
44. Ke C, Zhu X, Zhang Y, et al. Metabolomic characterization of hypertension and dyslipidemia. Metabolomics 2018;14:117.
45. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002;105:1816-23.
46. Belkner J, Chaitidis P, Stender H, et al. Expression of 12/15-lipoxygenase attenuates intracellular lipid deposition during in vitro foam cell formation. Arterioscler Thromb Vasc Biol 2005;25:797-802.
47. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species. Arterioscler Thromb Vasc Biol 2000;20:1716-23.
48. Dieber-Rotheneder M, Waeg G, Striegl G, et al. Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol 1990;3:77-92.
49. Ito J, Shimizu N, Kato S, et al. Direct separation of the diastereomers of cholesterol ester hydroperoxide using LC-MS/MS to evaluate enzymatic lipid oxidation. Symmetry 2020;12:1127.
50. Piotrowski JJ, Shah S, Alexander JJ. Mature human atherosclerotic plaque contains peroxidized phosphatidylcholine as a major lipid peroxide. Life Sci 1996;58:735-40.
51. Niki E, Noguchi N. Dynamics of oxidation of LDL and its inhibition by antioxidants. BioFactors 1997;6:201-8.
52. Belkner J, Stender H, Kühn H. The rabbit 15-lipoxygenase preferentially oxygenates LDL cholesterol esters, and this reaction does not require vitamin E. J Biol Chem 1998;273:23225-32.
53. Takahashi Y, Glasgow WC, Suzuki H, et al. Investigation of the oxygenation of phospholipids by the porcine leukocyte and human platelet arachidonate 12-lipoxygenases. Eur J Biochem 1993;218:165-71.
54. Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. Biochim Biophys Acta 1992;1128:117-31.
55. Funk CD. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1996;1304:65-84.
56. Zhu H, Takahashi Y, Xu W, et al. Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages. J Biol Chem 2003;278:13350-5.
57. Takahashi Y, Zhu H, Xu W, et al. Selective uptake and efflux of cholesteryl linoleate in LDL by macrophages expressing 12/15-lipoxygenase. Biochem Biophys Res Commun 2005;338:128-35.
58. Singh NK, Rao GN. Emerging role of 12/15-lipoxygenase (ALOX15) in human pathologies. Prog Lipid Res 2019;73:28.
59. Belkner J, Wiesner R, Rathman J, et al. Oxygenation of lipoproteins by mammalian lipoxygenases. Eur J Biochem 1993;213:251-61.
60. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 1989;86:1046-50.
61. Harats D, Shaish A, George J, et al. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2000;20:2100-5.
62. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA 1990;87:6959.
63. Hiltunen T, Luoma J, Nikkari T, et al. Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions. Circulation 1995;92:3297-303.
64. Santos LRB, Fleming I. Role of cytochrome P450-derived, polyunsaturated fatty acid mediators in diabetes and the metabolic syndrome. Prostaglandins Other Lipid Mediat 2020;148:106407.
65. Gomez I, Foudi N, Longrois D, et al. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot Essent Fatty Acids 2013;89:55-63.
66. Tang SY, Monslow J, Todd L, et al. Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation 2014;129:1761.
67. Spector AA, Kim HY. Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism. Biochim Biophys Acta 2015;1851:356.
68. Fissithaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-7.
69. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9.
70. Campbell WB, Gebremedhin D, Pratt PF, et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415-23.
72. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-5.
73. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349:1595-604.
74. Halliwell B, Gutteridge JMC. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 1986;246:501-14.
75. Lynch SM, Frei B. Mechanisms of copper- and iron-dependent oxidative modification of human low density lipoprotein. J Lipid Res 1993;3:1745-53.
76. Zhang Y, Murugesan P, Huang K, et al. NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets. Nat Rev Cardiol 2020;17:170.
77. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006;367:36-47.
78. Cheng C, Zheng E, Yu B, et al. Recognition of lipoproteins by scavenger receptor class A members. J Biol Chem 2021;297:100948.
79. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-8.
80. Chen B, Meng L, Shen T, et al. Thioredoxin attenuates oxidized low-density lipoprotein induced oxidative stress in human umbilical vein endothelial cells by reducing NADPH oxidase activity. Biochem Biophys Res Commun 2017;490:1326-33.
81. Frostegard J, Nilsson J, Haegerstrand A, et al. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990;87:904.
82. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:1876-90.
83. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-25.
84. Li Y, Li Y, Yang T, et al. Dioscin attenuates oxLDL uptake and the inflammatory reaction of dendritic cells under high glucose conditions by blocking p38 MAPK. Mol Med Rep 2020;21:304-10.
85. Gorog P, Born GVR. Nifedipine inhibits accumulation of LDL and cholesterol in the aorta of the normocholesterolemic rabbit. Arterioscler Thromb Vasc Biol 1993;13:637-9.
86. Bhakdi S, Dorweiler B, Kirchmann R, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995;182:1959-71.
87. Maaninka K, Nguyen SD, Mäyränpää MI, et al. Human mast cell neutral proteases generate modified LDL particles with increased proteoglycan binding. Atherosclerosis 2018;275:390-9.
88. Torzewski M, Suriyaphol P, Paprotka K, et al. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler Thromb Vasc Biol 2004;24:2130-6.
89. Han SR, Momeni A, Strach K, et al. Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early atherogenesis. Arterioscler Thromb Vasc Biol 2003;23:661-7.
90. Öörni K, Sneck M, Brömme D, et al. Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro. J Biol Chem 2004;279:34776-84.
91. Lindstedt L, Lee M, Castro GR, et al. Chymase-containing mast cells in human arterial intima: implications for atherosclerotic disease. J Clin Investig 1996;97:2174-82.
92. Öörni K, Hakala JK, Annila A, et al. Sphingomyelinase induces aggregation and fusion, but phospholipase A2 only aggregation, of low density lipoprotein (LDL) particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans. J Biol Chem 1998;273:29127-34.
93. Piha M, Lindstedt L, Kovanen PT. Fusion of proteolyzed low-density lipoprotein in the fluid phase: a novel mechanism generating atherogenic lipoprotein particles. Biochemistry 1995;34:10120-9.
94. Chellan B, Reardon CA, Getz GS, et al. Enzymatically modified low-density lipoprotein promotes foam cell formation in smooth muscle cells via macropinocytosis and enhances receptor-mediated uptake of oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 2016;36:1101-13.
95. Hui DY. Phospholipase A2 enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol 2012;23:235.
96. Elinder LS, Dumitrescu A, Larsson P, et al. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997;17:2257-63.
97. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2523-9.
98. Lehti S, Nguyen SD, Belevich I, et al. Extracellular lipids accumulate in human carotid arteries as distinct three-dimensional structures and have proinflammatory properties. Am J Pathol 2018;188:525-38.
99. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61.
100. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 1995;92:1355-74.
101. Hakala JK, Oksjoki R, Laine P, et al. Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2003;23:1430-6.
102. Heffron SP, Ruuth MK, Xia Y, et al. Low-density lipoprotein aggregation predicts adverse cardiovascular events in peripheral artery disease. Atherosclerosis 2021;316:53-7.
103. Ruuth M, Nguyen SD, Vihervaara T, et al. Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths. Eur Heart J 2018;39:2562-73.
104. Torzewski M. Enzymatically modified LDL, atherosclerosis and beyond: paving the way to acceptance. Front Biosci 2018;23:1257-71.
105. Arlaud GJ, Biro A, Ling WL. Enzymatically modified low-density lipoprotein is recognized by c1q and activates the classical complement pathway. J Lipids 2011;2011:1-5.
106. Martin-Ventura JL, Martinez-Lopez D, Roldan-Montero R, et al. Role of complement system in pathological remodeling of the vascular wall. Mol Immunol 2019;114:207-15.
107. Oksjoki R, Kovanen PT, Pentikäinen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003;14:477-82.
108. Oestvang J, Bonnefont-Rousselot D, Ninio E, et al. Modification of LDL with human secretory phospholipase A2 or sphingomyelinase promotes its arachidonic acid-releasing propensity. J Lipid Res 2004;45:831-8.
109. Taylor J, Butcher M, Zeadin M, et al. Oxidized low-density lipoprotein promotes osteoblast differentiation in primary cultures of vascular smooth muscle cells by up-regulating Osterix expression in an Msx2-dependent manner. J Cell Biochem 2011;112:581-8.
110. Liu J, Ren Y, Kang L, et al. Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin. Int J Mol Med 2014;33:1341-7.
111. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007;17:253-8.
112. Myasoedova VA, Di Minno A, Songia P, et al. Sex-specific differences in age-related aortic valve calcium load: a systematic review and meta-analysis. Ageing Res Rev 2020;61:101077.
113. Twardowski L, Cheng F, Michaelsen J, et al. Enzymatically modified low-density lipoprotein is present in all stages of aortic valve sclerosis: implications for pathogenesis of the disease. J Am Heart Assoc 2015;4:e002156.
114. Pavoine C, Pecker F. Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 2009;82:175.
115. Wang W, Zhang J, Wu W, et al. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS One 2011;6:e23425.
116. Melnichenko AA, Aksenov DV, Myasoedova VA, et al. Pluronic block copolymers inhibit low density lipoprotein self-association. Lipids 2012;47:995-1000.
117. Chazov EI, Orekhov AN, Perova NV, et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet 1986;328:595-8.
118. Orekhov AN, Tertov VV, Pokrovsky SN, et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res 1988;62:421-9.
119. Tertov VV, Orekhov AN, Kacharava AG, et al. Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Exp Mol Pathol 1990;52:300-8.
120. Tertov VV, Sobenin IA, Tonevitsky AG, et al. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem Biophys Res Commun 1990;167:1122-7.
121. Tertov VV, Bittolo-Bon G, Sobenin IA, et al. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol 1995;62:166-72.
122. Tertov VV, Sobenin IA, Gabbasov ZA, et al. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization. Lab Invest 1992;67:665-75.
123. Tertov VV, Kaplun VV, Sobenin IA, et al. Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis 2001;159:103-15.
124. Glanz VY, Myasoedova VA, Grechko AV, et al. Trans-sialidase associated with atherosclerosis: defining the identity of a key enzyme involved in the pathology. Curr Drug Targets 2019;20:938-41.
125. Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer 2021;124:76.
126. Li F, Ding J. Sialylation is involved in cell fate decision during development, reprogramming and cancer progression. Protein Cell 2019;10:550.
127. MacAuley MS, Crocker PR, Paulson JC. Siglec regulation of immune cell function in disease. Nat Rev Immunol 2014;14:653.
128. Zhang C, Chen J, Liu Y, et al. Sialic acid metabolism as a potential therapeutic target of atherosclerosis. Lipids Health Dis 2019;18:173.
129. Makarava N, Chang JCY, Baskakov IV. Region-specific sialylation pattern of prion strains provides novel insight into prion neurotropism. Int J Mol Sci 2020;21:828.
130. Bongiovanni A, Cusimano A, Annunziata I, et al. Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: a hypothesis. FASEB Bioadv 2021;3:192.
131. Betteridge KB, Arkill KP, Neal CR, et al. Sialic acids regulate microvessel permeability, revealed by novel in vivo studies of endothelial glycocalyx structure and function. J Physiol 2017;595:5015.
132. Eguchi H, Ikeda Y, Ookawara T, et al. Modification of oligosaccharides by reactive oxygen species decreases sialyl lewis x-mediated cell adhesion. Glycobiology 2005;15:1094-101.
133. Tanaka K, Tokumaru S, Kojo S. Possible involvement of radical reactions in desialylation of LDL. FEBS Lett 1997;413:202-4.
134. Iijima R, Takahashi H, Ikegami S, et al. Characterization of the reaction between sialic acid (N-acetylneuraminic acid) and hydrogen peroxide. Biol Pharm Bull 2007;30:580-2.
135. Yasuda J, Eguchi H, Fujiwara N, et al. Reactive oxygen species modify oligosaccharides of glycoproteins in vivo: a study of a spontaneous acute hepatitis model rat (LEC rat). Biochem Biophys Res Commun 2006;342:127-34.
136. Öztürk Z, Sönmez H, Görgün FM, et al. The relationship between lipid peroxidation and LDL desialylation in experimental atherosclerosis. Toxicol Mech Methods 2007;17:265-73.
137. Sukhorukov V, Gudelj I, Pučić-Baković M, et al. Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties. Biochim Biophys Acta Mol Cell Biol Lipids 2019;1864:643-53.
138. Igdoura SA, Gafuik C, Mertineit C, et al. Cloning of the cDNA and gene encoding mouse lysosomal sialidase and correction of sialidase deficiency in human sialidosis and mouse SM/J fibroblasts. Hum Mol Genet 1998;7:115-20.
139. Monti E, Preti A, Rossi E, et al. Cloning and characterization of NEU2, a human gene homologous to rodent soluble sialidases. Genomics 1999;57:137-43.
140. Miyagi T, Wada T, Iwamatsu A, et al. Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides. J Biol Chem 1999;274:5004-11.
141. Comelli EM, Amado M, Lustig SR, et al. Identification and expression of Neu4, a novel murine sialidase. Gene 2003;321:155-61.
142. White EJ, Gyulay G, Lhoták Š, et al. Sialidase down-regulation reduces non-HDL cholesterol, inhibits leukocyte transmigration, and attenuates atherosclerosis in ApoE knockout mice. J Biol Chem 2018;293:14689.
143. Demina EP, Smutova V, Pan X, et al. Neuraminidases 1 and 3 trigger atherosclerosis by desialylating low-density lipoproteins and increasing their uptake by macrophages. J Am Hear Assoc Cardiovasc Cerebrovasc Dis 2021;10:1-38.
144. Bowles WHD, Gloster TM. Sialidase and sialyltransferase inhibitors: targeting pathogenicity and disease. Front Mol Biosci 2021;8:705.
145. Tertov VV, Nikonova EY, Nifant’ev NE, et al. Human plasma trans-sialidase donor and acceptor specificity. Biochemistry 2002;67:908-13.
146. Mehr K, Withers SG. Mechanisms of the sialidase and trans-sialidase activities of bacterial sialyltransferases from glycosyltransferase family 80. Glycobiology 2016;26:353-9.
148. Suo J, Zhao L, Wang J, et al. Influenza virus aggravates the ox-LDL-induced apoptosis of human endothelial cells via promoting p53 signaling. J Med Virol 2015;87:1113-23.
149. Glanz VY, Kashirskikh DA, Grechko AV, et al. Sialidase activity in human blood serum has a distinct seasonal pattern: a pilot study. Biology 2020;9:1-7.
150. Cha SK, Ortega B, Kurosu H, et al. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci USA 2008;105:9805-10.
151. Cha SK, Hu MC, Kurosu H, et al. Regulation of renal outer medullary potassium channel and renal K+ excretion by Klotho. Mol Pharmacol 2009;76:38-46.
152. Yao Y, Wang Y, Zhang Y, et al. Klotho ameliorates oxidized low density lipoprotein (ox-LDL)-induced oxidative stress via regulating LOX-1 and PI3K/Akt/eNOS pathways. Lipids Health Dis 2017:16.
153. Tomin A, Dumych T, Tolstyak Y, et al. Desialylation of dying cells with catalytically active antibodies possessing sialidase activity facilitate their clearance by human macrophages. Clin Exp Immunol 2015;179:17.
154. Mcdowell A, Young IS, Wisdom GB. Measurement of asialylated LDL in the blood of patients with coronary artery disease by antibody-lectin sandwich assay. Ann Clin Biochem 2001;38:499-508.
155. Sobenin IA, Galitsyna EV, Grechko AV, et al. Small dense and desialylated low density lipoprotein in diabetic patients. Vessel Plus 2017;1:29-37.
156. Tertov VV, Sobenin IA, Gabbasov ZA, et al. Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem Biophys Res Commun 1989;163:489-94.
157. Tertov VV, Orekhov AN. Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima. Exp Mol Pathol 1997;64:127-45.
158. Aksenov DV, Medvedeva LA, Skalbe TA, et al. Deglycosylation of apo B-containing lipoproteins increase their ability to aggregate and to promote intracellular cholesterol accumulation in vitro. Arch Physiol Biochem 2008;114:349-56.[DOI:10.1080/13813450802227915].
159. Grewal T, Bartlett A, Burgess JW, et al. Desialylated LDL uptake in human and mouse macrophages can be mediated by a lectin receptor. Atherosclerosis 1996;121:151-63.
160. Tertov VV, Orekhov AN, Ryong LH, et al. Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cells. Tissue Cell 1988;20:849-54.
161. Doucet C, Huby T, Ruiz J, et al. Non-enzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis 1995;118:135-43.
162. Creriche AG, Stahl AJC. Glycation and oxidation of human low density lipoproteins reduces heparin binding and modifies charge. Scand J Clin Lab Invest 2009;53:125-32.
163. Akanji AO, Abdella N, Mojiminiyi OA. Determinants of glycated LDL levels in nondiabetic and diabetic hyperlipidaemic patients in Kuwait. Clin Chim Acta 2002;317:171-6.
164. Younis NN, Soran H, Pemberton P, et al. Small dense LDL is more susceptible to glycation than more buoyant LDL in type 2 diabetes. Clin Sci 2013;124:343-9.
165. Bucala R, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441.
166. Witztum JL, Mahoney EM, Branks MJ, et al. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1982;31:283-91.
167. Siddiqui K, George TP, Nawaz SS, et al. Significance of glycated LDL in different stages of diabetic nephropathy. Diabetes Metab Syndr Clin Res Rev 2019;13:548-52.
168. Bowie A, Owens D, Collins P, et al. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993;102:63-7.
169. Younis N, Charlton-Menys V, Sharma R, et al. Glycation of LDL in non-diabetic people: small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009;202:162-8.
170. Sobenin IA, Tertov VV, Koschinsky T, et al. Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 1993;100:41-54.
171. Sobenin IA, Tertov VV, Orekhov AN, et al. Synergetic effect of desialylated and glycated low density lipoproteins on cholesterol accumulation in cultured smooth muscle intimal cells. Atherosclerosis 1991;89:151-4.
172. Turco S, Basta G. An update on advanced glycation endproducts and atherosclerosis. BioFactors 2012;38:266-74.
173. De Michele G, Correale M, De Michele O, et al. Evaluation of serum biomarkers in nutritional disorders: glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects. Immunopharmacol Immunotoxicol 2008;30:925-36.
174. Misciagna G, Logroscino G, De Michele G, et al. Glycated apolipoprotein B and myocardial infarction. Nutr Metab Cardiovasc Dis 2007;17:6-12.
175. Salehi N, Janjani P, Tadbiri H, et al. Effect of cigarette smoking on coronary arteries and pattern and severity of coronary artery disease: a review. J Int Med Res 2021:49.
176. Nicholl ID, Stitt AW, Moore JE, et al. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med 1998;4:594.
177. Dickerson TJ, Janda KD. A previously undescribed chemical link between smoking and metabolic disease. Proc Natl Acad Sci USA 2002;99:15084.
178. Bucala R, Makita Z, Koschinsky T, et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434.
179. Yuan T, Yang T, Chen H, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol 2019;20:247.
180. Xiao ZL, Ma LP, Yang DF, et al. Profilin-1 is involved in macroangiopathy induced by advanced glycation end products via vascular remodeling and inflammation. World J Diabetes 2021;12:1875.
181. Mazzone A, Cusa C, Mazzucchelli I, et al. Cigarette smoking and hypertension influence nitric oxide release and plasma levels of adhesion molecules. Clin Chem Lab Med 2001;39:822-6.
182. Järvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004;109:1750-5.
183. Hajar R. Risk factors for coronary artery disease: historical perspectives. Heart Views 2017;18:109.
184. Delanghe S, Delanghe JR, Speeckaert R, et al. Mechanisms and consequences of carbamoylation. Nat Rev Nephrol 2017;13:580-93.[DOI:10.1038/NRNEPH.2017.103].
185. Jaisson S, Pietrement C, Gillery P. Protein carbamylation: chemistry, pathophysiological involvement, and biomarkers. Adv Clin Chem 2018;84:1-38.
186. Ok E, Basnakian AG, Apostolov EO, et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005;68:173-8.
187. Staplin N, Haynes R, Herrington WG, et al. Smoking and adverse outcomes in patients with CKD: the study of heart and renal protection (SHARP). Am J Kidney Dis 2016;68:371.
188. Valdivielso JM, Rodríguez-Puyol D, Pascual J, et al. Atherosclerosis in chronic kidney disease. Arterioscler Thromb Vasc Biol 2019;39:1938-66.
189. Russo E, Verzola D, Cappadona F, et al. The role of uric acid in renal damage - a history of inflammatory pathways and vascular remodeling. Vessel Plus 2021;5:15.
190. Apostolov EO, Ray D, Savenka AV, et al. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010;21:1852.
191. Kumar J, Shah SV. Kidney disease as an independent risk factor for cardiovascular events. J Ren Nutr 2005;15:99-104.
192. Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1176-84.
193. Stankova T, Delcheva G, Maneva A, et al. Serum levels of carbamylated LDL and soluble lectin-like oxidized low-density lipoprotein receptor-1 are associated with coronary artery disease in patients with metabolic syndrome. Medicina 2019;55:493.
194. Holy EW, Akhmedov A, Speer T, et al. Carbamylated low-density lipoproteins induce a prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo. J Am Coll Cardiol 2016;68:1664-76.
195. Bose C, Shah SV, Karaduta OK, et al. Carbamylated low-density lipoprotein (cLDL)-mediated induction of autophagy and its role in endothelial cell injury. PLoS One 2016;11:e0165576.
196. Asci G, Basci A, Shah SV, et al. Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells. Nephrology 2008;13:480-6.
197. Apostolov EO, Shah SV, Ok E, et al. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2007;27:826-32.
